Treatment of Psychosis and Agitation in Alzheimer's Disease
Treatment of Agitation in Alzheimer's Disease
Sponsor: National Institute on Aging NIA
Enrolling: Male and Female Patients
Study Length: 12 Weeks
Clinic Visits: 8
IRB Number: 6915
U.S. Govt. ID: NCT02129348
Contact: Laura Simon-Pearson: 646-774-8671 /
Additional Study Information: This NIH funded research study involves a 12-week double blind treatment trial in which Alzheimer's disease (ages 55-95) who have agitation/aggression with or without psychosis (hallucinations or delusions) will receive either low-dose lithium or placebo. Patients are allowed to receive other specific psychiatric medications if needed during the study, and will be closely monitored by physicians who specialize in memory disorders. Patients will receive open treatment with lithium, if clinically indicated, after completing the 12-week double blind trial.
This study is closed
Davangere Devanand, MD
Do You Qualify?
Do you or your loved one have Alzheimer's disease? Yes No
Do you or your loved one have agitation or aggression due to Alzheimer's disease? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Laura Simon-Pearson